Gleave M - Search Results

1

Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.

So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. So A, et al. Among authors: gleave m. Mol Cancer Ther. 2005 Dec;4(12):1837-49. doi: 10.1158/1535-7163.MCT-05-0178. Mol Cancer Ther. 2005. PMID: 16373699

2

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

3

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

4

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

5

Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Gleave ME, et al. Urology. 1999 Dec;54(6A Suppl):36-46. doi: 10.1016/s0090-4295(99)00453-7. Urology. 1999. PMID: 10606283

6

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

Miayake H, Tolcher A, Gleave ME. Miayake H, et al. Among authors: gleave me. J Natl Cancer Inst. 2000 Jan 5;92(1):34-41. doi: 10.1093/jnci/92.1.34. J Natl Cancer Inst. 2000. PMID: 10620631

7

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jan 1;60(1):170-6. Cancer Res. 2000. PMID: 10646870

8

Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 May 1;60(9):2547-54. Cancer Res. 2000. PMID: 10811138

9

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

Miyake H, Chi KN, Gleave ME. Miyake H, et al. Among authors: gleave me. Clin Cancer Res. 2000 May;6(5):1655-63. Clin Cancer Res. 2000. PMID: 10815883

10

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model.

Miyake H, Monia BP, Gleave ME. Miyake H, et al. Among authors: gleave me. Int J Cancer. 2000 Jun 15;86(6):855-62. doi: 10.1002/(sici)1097-0215(20000615)86:6<855::aid-ijc15>3.0.co;2-8. Int J Cancer. 2000. PMID: 10842201

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters